
Eli Lilly $3.8B Vaccine Acquisitions: Infectious Disease R&D
Examine Eli Lilly's $3.8B acquisition of three biotechs to build an infectious disease vaccine pipeline targeting shingles, EBV, and resistant bacteria.

Examine Eli Lilly's $3.8B acquisition of three biotechs to build an infectious disease vaccine pipeline targeting shingles, EBV, and resistant bacteria.

Analyze Pfizer's $10B acquisition of Metsera and the evolving GLP-1 obesity drug market. Learn about competing pipelines, clinical data, and pharma strategy.

Analyze the Chai Discovery and Eli Lilly partnership in AI biologics design. Examine how generative models like Chai-2 impact antibody drug development.
© 2026 IntuitionLabs. All rights reserved.